Volume 4, Number 1—March 1998
Synopsis
Proteases of Malaria Parasites: New Targets for Chemotherapy
Philip J. Rosenthal
Table 2
New antimalarial drugs
| Drug | Role | Best Feature(s) | Limitations |
|---|---|---|---|
| Halofantrine | TX of Pf malaria; not approved for CP | Usually effective against R Pf malaria | Variable bioavailability, cardiac toxicity |
| Artemisinin and related compoundsa | TX of Pf malaria | Rapidly acting; effective against multidrug-R strains | Recurrence after TX fairly common |
| Atovaquone | ? TX of Pf malaria; ? CP (probably in combination with proguanil) | Limited toxicity | Limited studies so far show frequent recurrence after TX |
| Pyronaridinea | ? TX of Pf malaria | Effective against R strains | Studies limited to date |
| Desferrioxamine | ? TX of severe Pf malaria | Well tolerated when used for iron overload | Studies limited to date |
| Azithromycin | ? CP | Limited toxicity | Studies limited to date |
For abbreviations, see Table 1, footnote a.
aNot available in the United States.
Page created: December 13, 2010
Page updated: December 13, 2010
Page reviewed: December 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.